Chief Medical Officer, La Jolla Pharmaceuticals Company
Dr. Chawla joined La Jolla Pharmaceuticals in 2015, and previously was a Professor of Medicine at the George Washington University, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. He was also the Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center. Dr. Chawla designed and led the ATHOS 3 Phase 3 trial for La Jolla Pharmaceutical’s FDA-approved drug for shock, GiaprezaTM. He is an internationally renowned expert in the field of acute care and especially acute kidney injury, and is the author of over 100 peer-reviewed publications.